新型siRNA降压药物Zilebesiran的研究现状  

Research status on the novel siRNA antihypertensive drug Zilebesiran

作　　者：杨蕙嫚 张景昌 Yang Huiman;Zhang Jingchang(Department of Cardiovascular Medicine,the Third Affiliated Hospital of Guangxi Medical University,Nanning 530000,China)

机构地区：[1]广西医科大学第三附属医院(南宁市第二人民医院)心血管内科,广西南宁530000

出　　处：《实用药物与临床》2024年第12期947-951,共5页Practical Pharmacy and Clinical Remedies

摘　　要：高血压是一种发病率极高且可以预防的心血管疾病。但由于患者的依从性不佳,仍有50%以上的高血压患者未达到降压指南推荐的目标血压水平。近年来,高血压的治疗已取得显著进展,其中以肝血管紧张素原(Angiotensinogen,AGT)为治疗靶点的小干扰RNA(siRNA)治疗药物Zilebesiran尤为引人瞩目。Zilebesiran作为一种新型siRNA治疗药物,通过抑制肝AGT的合成,展现了持续降压的潜力及良好的安全性。本文主要对Zilebesiran治疗高血压的研究现状进行综述,以期为未来Zilebesiran的临床应用提供理论依据。Hypertension is a highly prevalent and preventable cardiovascular disease.However,due to nonadherence to patient treatment,well over half of existing hypertensive patients have not yet reached the target blood pressure levels recommended by antihypertensive guidelines.In recent years,significant progress has been made in the field of hypertension treatment,with Zilebesiran,a small interfering RNA(siRNA)therapeutic drug that targets hepatic angiotensinogen(AGT),attracting particular attention.Zilebesiran,a novel siRNA therapeutic drug,realizes the potential of continuous hypotension and has good safety by inhibiting hepatic AGT synthesis.This article mainly reviews the current research status of Zilebesiran for the treatment of hypertension,with a view to providing theoretical support for the future clinical application of Zilebesiran.

关 键 词：Zilebesiran 小干扰RNA 肝血管紧张素原 高血压 

分 类 号：R972.4[医药卫生—药品]